Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial
In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin–paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings. HRQoL was measured with the EORTC QoL-Q...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2012-08, Vol.23 (8), p.2020-2027 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2027 |
|---|---|
| container_issue | 8 |
| container_start_page | 2020 |
| container_title | Annals of oncology |
| container_volume | 23 |
| creator | Brundage, M. Gropp, M. Mefti, F. Mann, K. Lund, B. Gebski, V. Wolfram, G. Reed, N. Pignata, S. Ferrero, A. Brown, C. Eisenhauer, E. Pujade-Lauraine, E. |
| description | In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin–paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings.
HRQoL was measured with the EORTC QoL-QC30 questionnaire and OV28 ovarian cancer module. Mean change scores from baseline in HRQoL subscales (five functional scales and global health status) in each arm and the proportion of patients improved or worsened were calculated every 3 months until 12 months.
Compliance was 90% at baseline and 76%, 64%, 57% at 3, 6, and 9 months, respectively. Baseline HRQoL showed already impaired global scores (mean 62/100) and considerable symptom burden (90% of patients reporting nonzero scores). Global QoL and abdominal symptom scores improved over time in both arms; at 6 months, 36% of patients met criteria for improved symptoms. Treatment with CD resulted in less peripheral neuropathy (9.8 versus 24.2), fewer other chemotherapy side-effects (9.5 versus 16.2), and less impact on body image (3.8 versus 10.4) versus CP (all P |
| doi_str_mv | 10.1093/annonc/mdr583 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdr583</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419381001</els_id><sourcerecordid>22291207</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-4b2d62884c20facadbc6383e94106a5c075c36db8b4e72deb2a0fd883b2455763</originalsourceid><addsrcrecordid>eNp10L1OwzAQwHELgWgpjKzIC2OoY8eJM6KKLwmpSMDAFDn2RTVKnGI7ldh4CJ6QJ8FVCkxMHvzT6e6P0GlKLlJSsrm0trdq3mnHBdtD05TnZSJIlu6jKSkpSwrOsgk68v6VEJKXtDxEE0ppmVJSTJG9BdmGVeKglQE0fhtka8I77hvcmgawsdiBGpwDG_A6GmOHLvFgvQlmA7jfSGekxUpaBe7r49OBH9rgceP6DocV4MXl_cvD4xKH6NpjdNDI1sPJ7p2h5-urp8Vtcr-8uYsyUVlKQpLVVOdUiExR0kglda1yJhiU8TeXXJGCK5brWtQZFFRDTSVptBCsphnnRc5mKBnnKtd776Cp1s500r1XKam23aqxWzV2i_5s9Ouh7kD_6p9QEZzvgPRKto2L9xr_5_JUcM63g4rRQbxuY8BVXhmIbbSJHUOle_PPCt_hOY7R</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Brundage, M. ; Gropp, M. ; Mefti, F. ; Mann, K. ; Lund, B. ; Gebski, V. ; Wolfram, G. ; Reed, N. ; Pignata, S. ; Ferrero, A. ; Brown, C. ; Eisenhauer, E. ; Pujade-Lauraine, E.</creator><creatorcontrib>Brundage, M. ; Gropp, M. ; Mefti, F. ; Mann, K. ; Lund, B. ; Gebski, V. ; Wolfram, G. ; Reed, N. ; Pignata, S. ; Ferrero, A. ; Brown, C. ; Eisenhauer, E. ; Pujade-Lauraine, E.</creatorcontrib><description>In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin–paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings.
HRQoL was measured with the EORTC QoL-QC30 questionnaire and OV28 ovarian cancer module. Mean change scores from baseline in HRQoL subscales (five functional scales and global health status) in each arm and the proportion of patients improved or worsened were calculated every 3 months until 12 months.
Compliance was 90% at baseline and 76%, 64%, 57% at 3, 6, and 9 months, respectively. Baseline HRQoL showed already impaired global scores (mean 62/100) and considerable symptom burden (90% of patients reporting nonzero scores). Global QoL and abdominal symptom scores improved over time in both arms; at 6 months, 36% of patients met criteria for improved symptoms. Treatment with CD resulted in less peripheral neuropathy (9.8 versus 24.2), fewer other chemotherapy side-effects (9.5 versus 16.2), and less impact on body image (3.8 versus 10.4) versus CP (all P < 0.02) at 6 months.
These patient-reported outcomes confirm the overall lower toxicity of CD versus CP. The improved disease-related outcomes achieved with CD were not at the expense of QoL.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdr583</identifier><identifier>PMID: 22291207</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; carboplatin ; Carboplatin - administration & dosage ; Carboplatin - adverse effects ; Doxorubicin - administration & dosage ; Doxorubicin - adverse effects ; Doxorubicin - analogs & derivatives ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Medication Adherence ; Neoplasm Recurrence, Local - drug therapy ; Ovarian Neoplasms - drug therapy ; paclitaxel ; Paclitaxel - administration & dosage ; Paclitaxel - adverse effects ; pegylated liposomal doxorubicin ; Pharmacology. Drug treatments ; platinum sensitive ; Polyethylene Glycols - administration & dosage ; Polyethylene Glycols - adverse effects ; Quality of Life ; recurrent ovarian cancer ; Tumors</subject><ispartof>Annals of oncology, 2012-08, Vol.23 (8), p.2020-2027</ispartof><rights>2012 European Society for Medical Oncology</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-4b2d62884c20facadbc6383e94106a5c075c36db8b4e72deb2a0fd883b2455763</citedby><cites>FETCH-LOGICAL-c410t-4b2d62884c20facadbc6383e94106a5c075c36db8b4e72deb2a0fd883b2455763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26185553$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22291207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brundage, M.</creatorcontrib><creatorcontrib>Gropp, M.</creatorcontrib><creatorcontrib>Mefti, F.</creatorcontrib><creatorcontrib>Mann, K.</creatorcontrib><creatorcontrib>Lund, B.</creatorcontrib><creatorcontrib>Gebski, V.</creatorcontrib><creatorcontrib>Wolfram, G.</creatorcontrib><creatorcontrib>Reed, N.</creatorcontrib><creatorcontrib>Pignata, S.</creatorcontrib><creatorcontrib>Ferrero, A.</creatorcontrib><creatorcontrib>Brown, C.</creatorcontrib><creatorcontrib>Eisenhauer, E.</creatorcontrib><creatorcontrib>Pujade-Lauraine, E.</creatorcontrib><title>Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin–paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings.
HRQoL was measured with the EORTC QoL-QC30 questionnaire and OV28 ovarian cancer module. Mean change scores from baseline in HRQoL subscales (five functional scales and global health status) in each arm and the proportion of patients improved or worsened were calculated every 3 months until 12 months.
Compliance was 90% at baseline and 76%, 64%, 57% at 3, 6, and 9 months, respectively. Baseline HRQoL showed already impaired global scores (mean 62/100) and considerable symptom burden (90% of patients reporting nonzero scores). Global QoL and abdominal symptom scores improved over time in both arms; at 6 months, 36% of patients met criteria for improved symptoms. Treatment with CD resulted in less peripheral neuropathy (9.8 versus 24.2), fewer other chemotherapy side-effects (9.5 versus 16.2), and less impact on body image (3.8 versus 10.4) versus CP (all P < 0.02) at 6 months.
These patient-reported outcomes confirm the overall lower toxicity of CD versus CP. The improved disease-related outcomes achieved with CD were not at the expense of QoL.</description><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>carboplatin</subject><subject>Carboplatin - administration & dosage</subject><subject>Carboplatin - adverse effects</subject><subject>Doxorubicin - administration & dosage</subject><subject>Doxorubicin - adverse effects</subject><subject>Doxorubicin - analogs & derivatives</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Medication Adherence</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>paclitaxel</subject><subject>Paclitaxel - administration & dosage</subject><subject>Paclitaxel - adverse effects</subject><subject>pegylated liposomal doxorubicin</subject><subject>Pharmacology. Drug treatments</subject><subject>platinum sensitive</subject><subject>Polyethylene Glycols - administration & dosage</subject><subject>Polyethylene Glycols - adverse effects</subject><subject>Quality of Life</subject><subject>recurrent ovarian cancer</subject><subject>Tumors</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10L1OwzAQwHELgWgpjKzIC2OoY8eJM6KKLwmpSMDAFDn2RTVKnGI7ldh4CJ6QJ8FVCkxMHvzT6e6P0GlKLlJSsrm0trdq3mnHBdtD05TnZSJIlu6jKSkpSwrOsgk68v6VEJKXtDxEE0ppmVJSTJG9BdmGVeKglQE0fhtka8I77hvcmgawsdiBGpwDG_A6GmOHLvFgvQlmA7jfSGekxUpaBe7r49OBH9rgceP6DocV4MXl_cvD4xKH6NpjdNDI1sPJ7p2h5-urp8Vtcr-8uYsyUVlKQpLVVOdUiExR0kglda1yJhiU8TeXXJGCK5brWtQZFFRDTSVptBCsphnnRc5mKBnnKtd776Cp1s500r1XKam23aqxWzV2i_5s9Ouh7kD_6p9QEZzvgPRKto2L9xr_5_JUcM63g4rRQbxuY8BVXhmIbbSJHUOle_PPCt_hOY7R</recordid><startdate>20120801</startdate><enddate>20120801</enddate><creator>Brundage, M.</creator><creator>Gropp, M.</creator><creator>Mefti, F.</creator><creator>Mann, K.</creator><creator>Lund, B.</creator><creator>Gebski, V.</creator><creator>Wolfram, G.</creator><creator>Reed, N.</creator><creator>Pignata, S.</creator><creator>Ferrero, A.</creator><creator>Brown, C.</creator><creator>Eisenhauer, E.</creator><creator>Pujade-Lauraine, E.</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20120801</creationdate><title>Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial</title><author>Brundage, M. ; Gropp, M. ; Mefti, F. ; Mann, K. ; Lund, B. ; Gebski, V. ; Wolfram, G. ; Reed, N. ; Pignata, S. ; Ferrero, A. ; Brown, C. ; Eisenhauer, E. ; Pujade-Lauraine, E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-4b2d62884c20facadbc6383e94106a5c075c36db8b4e72deb2a0fd883b2455763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>carboplatin</topic><topic>Carboplatin - administration & dosage</topic><topic>Carboplatin - adverse effects</topic><topic>Doxorubicin - administration & dosage</topic><topic>Doxorubicin - adverse effects</topic><topic>Doxorubicin - analogs & derivatives</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Medication Adherence</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>paclitaxel</topic><topic>Paclitaxel - administration & dosage</topic><topic>Paclitaxel - adverse effects</topic><topic>pegylated liposomal doxorubicin</topic><topic>Pharmacology. Drug treatments</topic><topic>platinum sensitive</topic><topic>Polyethylene Glycols - administration & dosage</topic><topic>Polyethylene Glycols - adverse effects</topic><topic>Quality of Life</topic><topic>recurrent ovarian cancer</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brundage, M.</creatorcontrib><creatorcontrib>Gropp, M.</creatorcontrib><creatorcontrib>Mefti, F.</creatorcontrib><creatorcontrib>Mann, K.</creatorcontrib><creatorcontrib>Lund, B.</creatorcontrib><creatorcontrib>Gebski, V.</creatorcontrib><creatorcontrib>Wolfram, G.</creatorcontrib><creatorcontrib>Reed, N.</creatorcontrib><creatorcontrib>Pignata, S.</creatorcontrib><creatorcontrib>Ferrero, A.</creatorcontrib><creatorcontrib>Brown, C.</creatorcontrib><creatorcontrib>Eisenhauer, E.</creatorcontrib><creatorcontrib>Pujade-Lauraine, E.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brundage, M.</au><au>Gropp, M.</au><au>Mefti, F.</au><au>Mann, K.</au><au>Lund, B.</au><au>Gebski, V.</au><au>Wolfram, G.</au><au>Reed, N.</au><au>Pignata, S.</au><au>Ferrero, A.</au><au>Brown, C.</au><au>Eisenhauer, E.</au><au>Pujade-Lauraine, E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2012-08-01</date><risdate>2012</risdate><volume>23</volume><issue>8</issue><spage>2020</spage><epage>2027</epage><pages>2020-2027</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>In the CALYPSO trial, carboplatin–pegylated liposomal doxorubicin (CD) demonstrated superior therapeutic index versus carboplatin–paclitaxel (CP) in patients with recurrent ovarian cancer. This paper reports the health-related quality of life (HRQoL) findings.
HRQoL was measured with the EORTC QoL-QC30 questionnaire and OV28 ovarian cancer module. Mean change scores from baseline in HRQoL subscales (five functional scales and global health status) in each arm and the proportion of patients improved or worsened were calculated every 3 months until 12 months.
Compliance was 90% at baseline and 76%, 64%, 57% at 3, 6, and 9 months, respectively. Baseline HRQoL showed already impaired global scores (mean 62/100) and considerable symptom burden (90% of patients reporting nonzero scores). Global QoL and abdominal symptom scores improved over time in both arms; at 6 months, 36% of patients met criteria for improved symptoms. Treatment with CD resulted in less peripheral neuropathy (9.8 versus 24.2), fewer other chemotherapy side-effects (9.5 versus 16.2), and less impact on body image (3.8 versus 10.4) versus CP (all P < 0.02) at 6 months.
These patient-reported outcomes confirm the overall lower toxicity of CD versus CP. The improved disease-related outcomes achieved with CD were not at the expense of QoL.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>22291207</pmid><doi>10.1093/annonc/mdr583</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2012-08, Vol.23 (8), p.2020-2027 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdr583 |
| source | MEDLINE; Alma/SFX Local Collection; EZB Electronic Journals Library |
| subjects | Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences carboplatin Carboplatin - administration & dosage Carboplatin - adverse effects Doxorubicin - administration & dosage Doxorubicin - adverse effects Doxorubicin - analogs & derivatives Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Medication Adherence Neoplasm Recurrence, Local - drug therapy Ovarian Neoplasms - drug therapy paclitaxel Paclitaxel - administration & dosage Paclitaxel - adverse effects pegylated liposomal doxorubicin Pharmacology. Drug treatments platinum sensitive Polyethylene Glycols - administration & dosage Polyethylene Glycols - adverse effects Quality of Life recurrent ovarian cancer Tumors |
| title | Health-related quality of life in recurrent platinum-sensitive ovarian cancer—results from the CALYPSO trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-03T14%3A37%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Health-related%20quality%20of%20life%20in%20recurrent%20platinum-sensitive%20ovarian%20cancer%E2%80%94results%20from%20the%20CALYPSO%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Brundage,%20M.&rft.date=2012-08-01&rft.volume=23&rft.issue=8&rft.spage=2020&rft.epage=2027&rft.pages=2020-2027&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdr583&rft_dat=%3Cpubmed_cross%3E22291207%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/22291207&rft_els_id=S0923753419381001&rfr_iscdi=true |